Table 2.
Year of publication and Author | Number of patients | Therapya | Microvessel stainingb | Prognosis of patients with high MVDc | Correlation of hypervascularity and MVDd | Correlation of high VEGF and MVDe |
---|---|---|---|---|---|---|
1997 Tanigawa29 | 43 | RES | CD34 | Poor (DFS/OS) | NE | NE |
vWF | ||||||
1998 El Assal25 | 71 | RES | vWF | Poor (DFS) | 0 | 0 |
1999 Sun30 | 78 | RES | CD34 | Poor (DFS) | NE | NE |
2002 Poon21 | 100 | RES | CD34 | Poor (DFS) | NE | NE |
vWF | Poor (DFS) | |||||
2004 Nanashima31 | 81 | RES | CD34 | Favorable (DFS/OS) | NE | NE |
2005 Ho32 | 86 | RES | CD34 | Comparable (DFS) | NE | NE |
CD105 | Comparable (DFS) | |||||
2006 Yang33 | 113 | RES | CD34 | Comparable (OS) | NE | + |
CD105 | Poor (OS) | |||||
2006 Zhang34 | 82 | LT | CD34 | Poor (DFS, univariate) | NE | + |
2007 Yao35 | 105 | RES | CD34 | Poor (DFS/OS) | NE | 0 |
CD105 | Poor (DFS/OS) | + | ||||
Present series | 32 | RES | CD34 | Favorable (DFS/OS) | 0 (art) – (portal) | NE |
30 | LT | CD34 | Comparable (DFS/OS) |
NE not evaluated
aType of treatment for HCC. RES partial liver resection, LT liver transplantation
bAntibody used for detection of microvessels. vWF anti-von Willebrand factor (factor VIII), CD34 anti-CD34 antibody, CD105 anti-CD105 antibody
cPrognosis of patients with tumors with high MVD as compared to those with low MVD. DFS disease-free survival, OS overall survival
dCorrelation of hypervascularity as seen on contrast enhanced CT or angiography with MVD. +/−/0, positive, negative or no correlation
eCorrelation of vascular endothelial growth factor (VEGF) with MVD. +/−/0, positive, negative, or no correlation